Full profile
| Also known as | Huperzia serrata extract, HupA |
|---|---|
| Best for | Studied mostly in age-related memory contexts · Microgram-dosed cholinergic-support ingredient |
| Evidence grade | Grade C — Limited — early or small human trials |
| Studied dose range | 50–200 mcg daily (micrograms). Health Canada caps total Huperzine A at 200 mcg/day — at or below the studied-effective range. |
| Time to effect | Cholinergic action is acute, but cognitive endpoints in trials were measured over 8–16 weeks. |
| Best form | Purified Huperzine A or standardized Huperzia serrata extract with a stated microgram content per serving. |
Evidence, honestly graded
Positive RCTs are concentrated in dementia patients and Chinese adolescent-student cohorts with high risk of bias; in healthy adults the signal largely disappears (e.g. a randomized crossover trial in healthy adults found no cognitive benefit). Honest grade for a healthy-adult use case is C.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
Side effects
- Nausea, diarrhea, cramping
- Muscle twitching, excess salivation, sweating
- Slowed heart rate (bradycardia)
- Dizziness or restlessness
Who should avoid it or check first
- Pregnant or breastfeeding
- Seizure or epilepsy history
- Slow heart rate or cardiac conduction disorders
- Cardiovascular or blood-pressure conditions without review
Interactions
- Do not combine with cholinesterase-inhibitor drugs (e.g. donepezil)
- May interact with cholinergic and anticholinergic drugs, and with beta-blockers or other heart-rate-lowering medication — discuss with a clinician
Stacks well with
- L-Theanine
- Rhodiola Rosea
Use caution stacking with
- Citicoline and other cholinergics (compounds cholinergic load)
- Bacopa Monnieri (mild cholinergic activity — use caution)
What to look for on a label
- More is not better — this is a microgram-dosed enzyme inhibitor; overshooting drives side effects, not benefit.
- The label should state the dose in micrograms with manufacturing precision, plus the required cautions.
References
- Yang 2013, PLoS One — Alzheimer's meta-analysis. Improvement reported across 20 RCTs but overall trial quality was poor. PMID 24086396; doi:10.1371/journal.pone.0074916. Educational, not a product claim.
- Wessinger 2021, Int J Exerc Sci — healthy-adult crossover trial. No cognitive benefit in a randomized double-blind crossover trial in healthy adults. PMID 34567353. Educational.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
See how Huperzine-A compares on grade, dose, and goal in the Evidence Explorer.
